Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Next-generation protein drugs against ovarian and breast cancer

EF 2023-24

Résumé
Cancer is the leading cause of death in Canada. The Myc/Max/Ebox (M2EB) transcription pathway, the product of MYC protein overexpression, is amplified in up to 70% of cancers, notably breast cancer (BC) and ovarian cancer (OC). Inhibition of this pathway has shown to decrease tumor cell proliferation and suppress tumor growth. Targeting this pathway pharmacologically can be achieved with Myc or Max protein mimetics. M2EB Inhibitors (M2EBi) work by inhibiting the M2EB transcription pathway. M2EBi are a novel series of small proteins based on the sequence of Max, instead of Myc, seen with Omomyc previously. Results from Phase I clinical trials of Omomyc have shown efficacy in tumour inhibition, however, they have a half-life of 20 minutes and suffer from poor tissue distribution, minimizing their clinical use. Max has an in vivo half-life >1 day, therefore having improved pharmacokinetic (PK) parameters and were shown to inhibit M2EB transcriptional activity at low nM concentrations. We will determine the Absorption, Distribution, Metabolism and Excretion (ADME) characteristics along with efficacy and toxicity of novel M2EBi compounds in BC models in vitro and in vivo. This will be achieved through examining the M2EBi compounds in vitro in OC, BC, and non-cancer cells lines; ADME characteristics in mice; efficacy of optimized M2EBi compounds in MYC-overexpressing models of triple-negative breast cancer (TNBC). TNBC represents 10-15% of BC and is associated with high MYC amplification and poor patient outcomes. We will facilitate a new drug pipeline of protein drugs with favourable PK that can impact >70% of cancers with the potential to revolutionize cancer care, significantly enhancing healthcare and quality-of-life for cancer patients and their loved ones.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506114
Name
He Francine S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Next-generation protein drugs against ovarian and breast cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Animal Research; Breast Cancer; Drug Efficacy; Drug Toxicity; Oncology; Pharmacokinetics; Pharmacology
Abstract
Cancer is the leading cause of death in Canada. The Myc/Max/Ebox (M2EB) transcription pathway, the product of MYC protein overexpression, is amplified in up to 70% of cancers, notably breast cancer (BC) and ovarian cancer (OC). Inhibition of this pathway has shown to decrease tumor cell proliferation and suppress tumor growth. Targeting this pathway pharmacologically can be achieved with Myc or Max protein mimetics. M2EB Inhibitors (M2EBi) work by inhibiting the M2EB transcription pathway. M2EBi are a novel series of small proteins based on the sequence of Max, instead of Myc, seen with Omomyc previously. Results from Phase I clinical trials of Omomyc have shown efficacy in tumour inhibition, however, they have a half-life of 20 minutes and suffer from poor tissue distribution, minimizing their clinical use. Max has an in vivo half-life >1 day, therefore having improved pharmacokinetic (PK) parameters and were shown to inhibit M2EB transcriptional activity at low nM concentrations. We will determine the Absorption, Distribution, Metabolism and Excretion (ADME) characteristics along with efficacy and toxicity of novel M2EBi compounds in BC models in vitro and in vivo. This will be achieved through examining the M2EBi compounds in vitro in OC, BC, and non-cancer cells lines; ADME characteristics in mice; efficacy of optimized M2EBi compounds in MYC-overexpressing models of triple-negative breast cancer (TNBC). TNBC represents 10-15% of BC and is associated with high MYC amplification and poor patient outcomes. We will facilitate a new drug pipeline of protein drugs with favourable PK that can impact >70% of cancers with the potential to revolutionize cancer care, significantly enhancing healthcare and quality-of-life for cancer patients and their loved ones.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
He, Francine S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~